BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Budinger GRS, Misharin AV, Ridge KM, Singer BD, Wunderink RG. Distinctive features of severe SARS-CoV-2 pneumonia. J Clin Invest 2021;131:149412. [PMID: 34263736 DOI: 10.1172/JCI149412] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 23.0] [Reference Citation Analysis]
Number Citing Articles
1 Kinoshita T, Shinoda M, Nishizaki Y, Shiraki K, Hirai Y, Kichikawa Y, Tsushima K, Sinkai M, Komura N, Yoshida K, Kido Y, Kakeya H, Uemura N, Kadota J. A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study). BMC Med 2022;20:342. [PMID: 36163020 DOI: 10.1186/s12916-022-02518-7] [Reference Citation Analysis]
2 Gao CA, Markov NS, Stoeger T, Pawlowski A, Kang M, Nannapaneni P, Grant RA, Pickens C, Walter JM, Kruser JM, Rasmussen L, Schneider D, Starren J, Donnelly HK, Donayre A, Luo Y, Scott Budinger G, Wunderink RG, Misharin AV, Singer BD, The NU SCRIPT Study Investigators. A machine learning approach identifies unresolving secondary pneumonia as a contributor to mortality in patients with severe pneumonia, including COVID-19.. [DOI: 10.1101/2022.09.23.22280118] [Reference Citation Analysis]
3 Di Gaudio F, Brunacci G, Contino F, Gallo A, Centineo F. Technical and health governance aspects of the External Quality Assessment Scheme for the SARS-CoV-2 molecular tests: institutional experience performed in all clinical laboratories of a Regional Health Service. Clinical Chemistry and Laboratory Medicine (CCLM) 2022;0. [DOI: 10.1515/cclm-2022-0780] [Reference Citation Analysis]
4 Izzo R, Trimarco V, Mone P, Aloè T, Marzani MC, Diana A, Fazio G, Mallardo M, Maniscalco M, Marazzi G, Messina N, Mininni S, Mussi C, Pelaia G, Pennisi A, Santus P, Scarpelli F, Tursi F, Zanforlin A, Santulli G, Trimarco B. Combining L-Arginine with Vitamin C Improves Long-COVID Symptoms: The Nationwide Multicenter LINCOLN Study. Pharmacol Res 2022;:106360. [PMID: 35868478 DOI: 10.1016/j.phrs.2022.106360] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
5 Rahimi RA, Cho JL, Jakubzick CV, Khader SA, Lambrecht BN, Lloyd CM, Molofsky AB, Talbot S, Bonham CA, Drake WP, Sperling AI, Singer BD. Advancing Lung Immunology Research: An Official American Thoracic Society Workshop Report. Am J Respir Cell Mol Biol 2022;67:e1-18. [PMID: 35776495 DOI: 10.1165/rcmb.2022-0167ST] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Joudi AM, Reyes Flores CP, Singer BD. Epigenetic Control of Regulatory T Cell Stability and Function: Implications for Translation. Front Immunol 2022;13:861607. [PMID: 35309306 DOI: 10.3389/fimmu.2022.861607] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
7 Bain CC, Lucas CD, Rossi AG. Pulmonary macrophages and SARS-Cov2 infection. Int Rev Cell Mol Biol 2022;367:1-28. [PMID: 35461655 DOI: 10.1016/bs.ircmb.2022.01.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Kinoshita T, Shinoda M, Nishizaki Y, Shiraki K, Hirai Y, Kichikawa Y, Tsushima K, Sinkai M, Komura N, Yoshida K, Kido Y, Kakeya H, Uemura N, Kadota J. Phase 3, multicentre, double-blind, randomised, parallel-group, placebo-controlled study of camostat mesilate (FOY-305) for the treatment of COVID-19 (CANDLE study).. [DOI: 10.1101/2022.03.27.22271988] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Kurihara C, Manerikar A, Querrey M, Felicelli C, Yeldandi A, Garza-Castillon R Jr, Lung K, Kim S, Ho B, Tomic R, Arunachalam A, Budinger GRS, Pesce L, Bharat A. Clinical Characteristics and Outcomes of Patients With COVID-19-Associated Acute Respiratory Distress Syndrome Who Underwent Lung Transplant. JAMA 2022;327:652-61. [PMID: 35085383 DOI: 10.1001/jama.2022.0204] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 20.0] [Reference Citation Analysis]
10 Carr AC, Gombart AF. Multi-Level Immune Support by Vitamins C and D during the SARS-CoV-2 Pandemic. Nutrients 2022;14:689. [DOI: 10.3390/nu14030689] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Nelson-Sathi S, Umasankar PK, Sreekumar E, Nair RR, Joseph I, Nori SRC, Philip JS, Prasad R, Navyasree KV, Ramesh S, Pillai H, Ghosh S, Santosh Kumar TR, Pillai MR. Mutational landscape and in silico structure models of SARS-CoV-2 spike receptor binding domain reveal key molecular determinants for virus-host interaction. BMC Mol Cell Biol 2022;23:2. [PMID: 34991443 DOI: 10.1186/s12860-021-00403-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Guest PC, Zahedipour F, Majeed M, Jamialahmadi T, Sahebkar A. Multiplex Technologies in COVID-19 Research, Diagnostics, and Prognostics: Battling the Pandemic. Multiplex Biomarker Techniques 2022. [DOI: 10.1007/978-1-0716-2395-4_1] [Reference Citation Analysis]
13 Mylvaganam RJ, Bailey JI, Sznajder JI, Sala MA; Northwestern Comprehensive COVID Center Consortium. Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection. Eur Respir Rev 2021;30:210194. [PMID: 34911696 DOI: 10.1183/16000617.0194-2021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
14 Gil-Rodríguez J, Martos-Ruiz M, Peregrina-Rivas JA, Aranda-Laserna P, Benavente-Fernández A, Melchor J, Guirao-Arrabal E. Lung Ultrasound, Clinical and Analytic Scoring Systems as Prognostic Tools in SARS-CoV-2 Pneumonia: A Validating Cohort. Diagnostics (Basel) 2021;11:2211. [PMID: 34943448 DOI: 10.3390/diagnostics11122211] [Reference Citation Analysis]
15 Spencer E, Rosengrave P, Williman J, Shaw G, Carr AC. Circulating protein carbonyls are specifically elevated in critically ill patients with pneumonia relative to other sources of sepsis. Free Radic Biol Med 2021:S0891-5849(21)00827-3. [PMID: 34818575 DOI: 10.1016/j.freeradbiomed.2021.11.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
16 Wu N, Chen LK, Zhu T. Phage therapy for secondary bacterial infections with COVID-19. Curr Opin Virol 2021;52:9-14. [PMID: 34800893 DOI: 10.1016/j.coviro.2021.11.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
17 Michalski JE, Kurche JS, Schwartz DA. From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic? Transl Res 2021:S1931-5244(21)00243-7. [PMID: 34547499 DOI: 10.1016/j.trsl.2021.09.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 17.0] [Reference Citation Analysis]
18 Koch CM, Anekalla KR, Hu Y, Davis JM, Ciesielski M, Gadhvi G, Chen S, Turner M, Cheng Y, Coates BM, Abdala-valencia H, Reyfman PA, Misharin AV, Budinger GS, Winter DR, Ridge KM. Influenza-induced activation of recruited alveolar macrophages during the early inflammatory phase drives lung injury and lethality.. [DOI: 10.1101/2020.06.08.141309] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]